Brown Advisory’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-7,757
| Closed | -$554K | – | 1273 |
|
|
2023
Q4 | $554K | Buy |
+7,757
| New | +$554K | ﹤0.01% | 910 |
|
|
2019
Q2 | – | Sell |
-44,192
| Closed | -$3.47M | – | 1160 |
|
|
2019
Q1 | $3.47M | Buy |
44,192
+19,443
| +79% | +$1.52M | 0.01% | 516 |
|
|
2018
Q4 | $2.09M | Buy |
24,749
+10,962
| +80% | +$927K | 0.01% | 589 |
|
|
2018
Q3 | $2.36M | Sell |
13,787
-1,700
| -11% | -$291K | 0.01% | 606 |
|
|
2018
Q2 | $2M | Buy |
15,487
+2,766
| +22% | +$357K | 0.01% | 623 |
|
|
2018
Q1 | $1.31M | Sell |
12,721
-1,102
| -8% | -$113K | ﹤0.01% | 599 |
|
|
2017
Q4 | $1.18M | Sell |
13,823
-484
| -3% | -$41.4K | ﹤0.01% | 638 |
|
|
2017
Q3 | $1.22M | Buy |
14,307
+528
| +4% | +$44.8K | ﹤0.01% | 618 |
|
|
2017
Q2 | $1.04M | Buy |
13,779
+1,891
| +16% | +$143K | ﹤0.01% | 675 |
|
|
2017
Q1 | $785K | Buy |
11,888
+2,703
| +29% | +$178K | ﹤0.01% | 690 |
|
|
2016
Q4 | $582K | Buy |
9,185
+1,939
| +27% | +$123K | ﹤0.01% | 757 |
|
|
2016
Q3 | $461K | Buy |
7,246
+1,990
| +38% | +$127K | ﹤0.01% | 785 |
|
|
2016
Q2 | $391K | Sell |
5,256
-2,052
| -28% | -$153K | ﹤0.01% | 802 |
|
|
2016
Q1 | $488K | Sell |
7,308
-16
| -0.2% | -$1.07K | ﹤0.01% | 723 |
|
|
2015
Q4 | $495K | Sell |
7,324
-468
| -6% | -$31.6K | ﹤0.01% | 693 |
|
|
2015
Q3 | $417K | Buy |
7,792
+2,085
| +37% | +$112K | ﹤0.01% | 721 |
|
|
2015
Q2 | $359K | Sell |
5,707
-3,873
| -40% | -$244K | ﹤0.01% | 701 |
|
|
2015
Q1 | $461K | Buy |
9,580
+1,283
| +15% | +$61.7K | ﹤0.01% | 707 |
|
|
2014
Q4 | $276K | Buy |
8,297
+1,122
| +16% | +$37.3K | ﹤0.01% | 821 |
|
|
2014
Q3 | $211K | Buy |
7,175
+1,725
| +32% | +$50.7K | ﹤0.01% | 874 |
|
|
2014
Q2 | $212K | Buy |
5,450
+160
| +3% | +$6.22K | ﹤0.01% | 884 |
|
|
2014
Q1 | $222K | Buy |
+5,290
| New | +$222K | ﹤0.01% | 843 |
|